Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their ...

View Bio-Rad Laboratories, Inc. Class A BIO stock quote prices, financial information, real-time forecasts, and company news from CNN.

Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...

Bio-Rad's Q3 saw the company book $653 million in revenue, which was very modestly (0.5%) higher on a year-over-year basis. Net income not according to generally accepted accounting principles (GAAP) ...

We recently published a list of Billionaire Mason Hawkins’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc. (NYSE:BIO) ...

Bio-Rad Laboratories, Inc. BIO posted first-quarter 2025 adjusted earnings per share (EPS) of $2.54, which surpassed the Zacks Consensus Estimate of $1.73 by 46.8%. The bottom line increased 10.9% ...

BIO unveils four new ddPCR systems, enhancing its Life Science offerings post-Stilla Technologies acquisition. BIO's new systems improve workflow, precision and throughput across PCR applications in ...

BIO boosts ddPCR growth with the Stilla acquisition, QX700 launch and expanded assays for molecular testing. Bio-Rad's clinical diagnostics sees strong demand, led by IH-500 NEXT and growth in ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low.

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life ...